BCRX
Biocryst Pharmaceuticals Inc Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$8.47Close
$1.8BMarket cap
$6.24 – $11.1152-week range
Nov 4, 2026Next report · before the open
Highlights
Strengths
- Earnings growing EPS +1178% year on year, faster than the quarter before (+2005572 pts)
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
24%
1wk
up 10.7%
price change
1mo
up 1.7%
price change
12-month return
up 17%
market up 11% ·
its own up 5%
F-score
7 / 9
Strong
Altman Z
1.98
Moderate risk
P/E
6.8×
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
up 19.9%
EBIT / enterprise value
Cheaper than
98%
of the market · markedly cheap
Revenue growth
up 94%
year on year
EPS growth
up 1178%
latest quarter · +2005572 pts
Sales growth
up 34%
latest quarter · +26 pts
ROE
—
return on equity
Free cash margin
up 39%
$344.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-0.3×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- short-term liquidity weakened
- issued more shares
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- gross margin widened
- assets working harder
Repair signals
- FCF turned positive ($-53M → $345M)
- Long-term debt down 100% ($0.3B → $0.0B)
Trade setup
ATR%
3.6%
$0.31 a day · 2×ATR $7.86
RS
54 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
0.75
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$119.2M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Shareholders diluted The share count rose 2.2% over the year, from 209m to 213m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+3% vs market2 sessions after results
Financials
- Gross 98%
- Net 30%
- Free cash 39%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $17.8M | $157.2M | $270.8M | $331.4M | $450.7M | $874.8M |
| Gross margin | 91% | 95% | 98% | 99% | 97% | 98% |
| Operating income | -$174.8M | -$177.7M | -$148.4M | -$103.7M | -$2.5M | $341.0M |
| Net income | -$182.8M | -$184.1M | -$247.1M | -$226.5M | -$88.9M | $263.9M |
| Net margin | -1026% | -117% | -91% | -68% | -20% | 30% |
| Earnings per share | -$1.09 | -$1.03 | -$1.33 | -$1.18 | -$0.43 | $1.21 |
| Free cash flow | -$135.6M | -$144.5M | -$163.2M | -$97.3M | -$53.1M | $344.9M |
| Free cash margin | -761% | -92% | -60% | -29% | -12% | 39% |
| Cash | $272.1M | $504.4M | $304.8M | $110.6M | $104.7M | $89.7M |
| Long-term debt | $119.7M | $136.1M | $231.6M | $303.2M | $314.9M | $0 |
| Shareholders' equity | -$19.3M | -$107.0M | -$294.6M | -$455.5M | -$475.9M | -$119.2M |
| Shares outstanding | 176.88m | 184.35m | 187.91m | 205.77m | 208.54m | 213.06m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 5, 2026 | Results · Regulation FD ↗ |
| Jun 29, 2026 | Restructuring · Regulation FD ↗ |
| Jun 12, 2026 | Director or officer change · Shareholder vote ↗ |
| May 6, 2026 | Results · Regulation FD ↗ |
| May 4, 2026 | Regulation FD ↗ |
| Feb 26, 2026 | Results · Regulation FD ↗ |
| Jan 23, 2026 | Material agreement · Acquisition or disposal · New obligation · Regulation FD ↗ |
| Jan 12, 2026 | Results · Regulation FD · Other events ↗ |
| Jan 9, 2026 | Regulation FD ↗ |
| Dec 12, 2025 | Other events ↗ |
| Dec 11, 2025 | Director or officer change ↗ |
| Dec 3, 2025 | Other events ↗ |